What is the incidence of metastatic lymph node involvement after significant pathologic response of primary tumor following neoadjuvant treatment for locally advanced rectal cancer?
- PMID:23188545
- DOI: 10.1245/s10434-012-2773-9
What is the incidence of metastatic lymph node involvement after significant pathologic response of primary tumor following neoadjuvant treatment for locally advanced rectal cancer?
Abstract
Background: In locally advanced rectal cancer (LARC) patients, major response to neoadjuvant radiotherapy (NR) has been associated with favorable long-term outcomes. Positive pathologic nodal status was recently proven to be associated with poor prognosis even after total regression of primary tumor (ypT0). The aim of this study was to evaluate the rate of lymph node (LN) involvement in patients with complete (ypT0) or major (TRG1: very few viable tumor cells) response.
Methods: Included were patients with complete or major response after radiotherapy followed by surgery and histological examination of the whole specimen.
Results: From 1996 to 2010, 245 patients with LARC were treated by NR. We collected clinical data for 53 patients (21.6 %) with ypT0 (n = 26, 49 %) or TRG1 (n = 27, 51 %) response. Sphincter-preserving surgery was performed in 40 patients (75 %). Overall, nine patients (16.9 %) presented LN involvement: 2 (7.7 %) in the ypT0 group and 7 (25.9 %) in the TRG1 group (NS). Patients with ypT3 tumors had significantly more invaded LN than patients with ypT1-T2 tumors (6 of 13 [46 %] vs 1 of 14 [7 %], p = .032). After median follow-up of 30 months (range, 1-160 months), 5-year disease-free and overall survivals were 88.2 and 89.0 %, respectively.
Conclusions: There was a clear cutoff between patients with ypT0-T2 (3 of 40, 7.5 %) and ypT3 (6 of 13, 46 %) concerning the incidence of metastatic LN in patients achieving pathologic complete or major response after NR. In patients with good clinical response, local full-thickness resection of the residual tumor could be a first step, followed by standard rectal resection in cases of ypT3.
Similar articles
- [Lymph node metastases in ypT1/2 rectal cancer after neoadjuvant chemoradiotherapy : The Achilles heel of organ-preserving operative procedures?].Sprenger T, Rothe H, Beissbarth T, Conradi LC, Kauffels A, Homayounfar K, Behnes CL, Rödel C, Liersch T, Ghadimi M.Sprenger T, et al.Chirurg. 2016 Jul;87(7):593-601. doi: 10.1007/s00104-016-0170-9.Chirurg. 2016.PMID:27106241Clinical Trial.German.
- [Value of postoperative adjuvant chemotherapy in locally advanced rectal cancer patients with ypT1-4N0 after neo-adjuvant chemoradiotherapy].You KY, Peng HH, Gao YH, Chen L, Zhou GQ, Chang H, Du XJ, Xiao L, Zeng ZF, Wen BX, Liu MZ.You KY, et al.Zhonghua Zhong Liu Za Zhi. 2013 Sep;35(9):708-13.Zhonghua Zhong Liu Za Zhi. 2013.PMID:24332061Chinese.
- Does pathologic response of rectal cancer influence postoperative morbidity after neoadjuvant radiochemotherapy and total mesorectal excision?Maggiori L, Bretagnol F, Aslam MI, Guedj N, Zappa M, Ferron M, Panis Y.Maggiori L, et al.Surgery. 2014 Mar;155(3):468-75. doi: 10.1016/j.surg.2013.10.020. Epub 2013 Oct 22.Surgery. 2014.PMID:24439750
- [Research progress on pathologic complete response after neoadjuvant chemoradiotherapy for locally advanced rectal cancer].Peng HH, You KY, Gao YH, Wen BX.Peng HH, et al.Zhonghua Wei Chang Wai Ke Za Zhi. 2013 Jun;16(6):592-6.Zhonghua Wei Chang Wai Ke Za Zhi. 2013.PMID:23801217Review.Chinese.
- Pattern of Residual Submucosal Involvement after Neoadjuvant Therapy for Rectal Cancer: A Rationale for the Utility of Endoscopic Submucosal Resection.Elazzamy H, Bhatt M, Mazzara P, Barawi M, Zeni A, Aref A.Elazzamy H, et al.Medicina (Kaunas). 2023 Oct 11;59(10):1807. doi: 10.3390/medicina59101807.Medicina (Kaunas). 2023.PMID:37893525Free PMC article.Review.
Cited by
- The Norwegian Watch and Wait study: Norwait for rectal cancer. A report from a failed study-a word of caution.Wasmuth HH, Færden AE.Wasmuth HH, et al.Updates Surg. 2024 Sep;76(5):1635-1639. doi: 10.1007/s13304-024-01941-0. Epub 2024 Jul 14.Updates Surg. 2024.PMID:39003668
- Long-Term Outcome of Rectal Cancer With Clinically (EUS/MRI) Metastatic Mesorectal Lymph Nodes Treated by Neoadjuvant Chemoradiation: Role of Organ Preservation Strategies in Relation to Pathologic Response.Belluco C, Forlin M, Olivieri M, Cannizzaro R, Canzonieri V, Buonadonna A, Bidoli E, Matrone F, Bertola G, De Paoli A.Belluco C, et al.Ann Surg Oncol. 2016 Dec;23(13):4302-4309. doi: 10.1245/s10434-016-5451-5. Epub 2016 Aug 3.Ann Surg Oncol. 2016.PMID:27489059Free PMC article.
- A multicentric randomized controlled trial on the impact of lengthening the interval between neoadjuvant radiochemotherapy and surgery on complete pathological response in rectal cancer (GRECCAR-6 trial): rationale and design.Lefevre JH, Rousseau A, Svrcek M, Parc Y, Simon T, Tiret E; French Research Group of Rectal Cancer Surgery (GRECCAR).Lefevre JH, et al.BMC Cancer. 2013 Sep 12;13:417. doi: 10.1186/1471-2407-13-417.BMC Cancer. 2013.PMID:24028546Free PMC article.Clinical Trial.
- MR Imaging of Rectal Cancer: Radiomics Analysis to Assess Treatment Response after Neoadjuvant Therapy.Horvat N, Veeraraghavan H, Khan M, Blazic I, Zheng J, Capanu M, Sala E, Garcia-Aguilar J, Gollub MJ, Petkovska I.Horvat N, et al.Radiology. 2018 Jun;287(3):833-843. doi: 10.1148/radiol.2018172300. Epub 2018 Mar 7.Radiology. 2018.PMID:29514017Free PMC article.
- Can tumor regression grade influence survival outcome in ypT3 rectal cancer?Shen L, Wang L, Li G, Zhang H, Liang L, Fan M, Wu Y, Deng W, Sheng W, Zhu J, Zhang Z.Shen L, et al.Clin Transl Oncol. 2016 Jul;18(7):693-9. doi: 10.1007/s12094-015-1419-3. Epub 2015 Nov 2.Clin Transl Oncol. 2016.PMID:26527031
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Miscellaneous